Oric Pharmaceuticals financials
$13.37+0.75%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$45.3M | -$39.6M | -$34.6M | -$36.7M | -$39.1M | -$32.7M | -$39.6M | -$38.3M | -$36.0M | -$29.0M | -$31.4M | -$28.7M |
| Net income | -$41.5M | -$35.8M | -$30.5M | -$32.6M | -$36.4M | -$30.0M | -$36.3M | -$34.6M | -$32.0M | -$25.0M | -$28.3M | -$25.5M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.38 | $-0.34 | $-0.30 | $-0.33 | $-0.47 | $-0.42 | $-0.51 | $-0.49 | $-0.45 | $-0.37 | $-0.49 | $-0.44 |
| EBITDA | -$45.0M | -$39.3M | -$34.2M | -$36.4M | -$38.8M | -$32.4M | -$39.3M | -$38.0M | -$35.7M | -$28.7M | -$31.2M | -$28.4M |
| Operating cash flow | -$31.6M | -$32.4M | -$22.5M | -$25.1M | -$30.8M | -$32.5M | -$28.1M | -$28.8M | -$25.6M | -$30.2M | -$24.3M | -$19.6M |
| Free cash flow | -$32.0M | -$32.4M | -$22.7M | -$25.1M | -$30.9M | -$32.9M | -$28.3M | -$29.2M | -$26.0M | -$30.4M | -$24.3M | -$19.7M |
| Diluted shares | 108.0M | 105.5M | 103.1M | 99.0M | 78.1M | 71.0M | 70.7M | 70.5M | 70.3M | 67.3M | 57.7M | 57.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $37.5M | $56.4M | $45.7M | $49.7M | $75.9M | $49.3M |
| Short-term investments | $227.3M | $225.5M | $235.8M | $237.5M | $206.6M | $154.4M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $404.7M | $436.8M | $408.9M | $431.2M | $346.9M | $242.9M |
| Total liabilities | $23.4M | $21.2M | $24.5M | $24.3M | $22.9M | $23.1M |
| Shareholders' equity | $381.3M | $415.6M | $384.4M | $406.9M | $324.0M | $219.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology